-
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)
Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
Toll-Like Receptor (TLR) & Innate Sensing(Page) Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
Understanding Antibody Staining for Antigen Detection in Flow Cytometry(Post)Flow cytometry stands as a pivotal technique in the realms of molecular biology and immunology, enabling the analysis of physical and chemical characteristics of cells or particles as they flow in
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
CD31: A Comprehensive Look at an Essential Biomarker(Post)What is CD31? CD31, also known as PECAM-1, was originally described as a cell surface antigen present on platelets and megakaryocytes. CD31 is
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask(Post)Validate Western Blot Antibodies: Datasheet Checks Labs Should Ask Reliable results come from antibodies validated specifically for denatured western blot conditions: recombinant monoclonals or well-
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
Decoding the Language of Cells: Chemokine Signaling Pathways Unveiled(Post)Chemokines are small signaling proteins that play a crucial role in the immune system by directing the movement of cells, orchestrating immune responses, and maintaining tissue homeostasis. The
The Essential Guide to DNA: Components, Purpose and Purification Methods(Post)Exploring DNA's essence, this guide illuminates its structure, function, and purification techniques, essential in fields like medicine and biotechnology. Key Takeaways: DNA's Struct
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
TGF-β/SMAD signalling(Page) MAPK Signaling: Unraveling the Pathway of Mitogen Stimulation(Post)Cell Signalling · Kinase CascadesMAPK Signaling: The Pathway of Mitogen StimulationThe mitogen-activated protein kinase (MAPK) pathway is one of the most important signalling cascades in biology, conv
Exploring Organelle Markers: Illuminating the Cellular Landscape(Post)The eukaryotic cell is a complex and dynamic system with distinct membrane-bound compartments known as organelles, each performing specialized functions essential for cellular survival. To better
Microtubule and Mitosis review(Post)Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
Platelets and Immunothrombosis (Page) The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.